Devon J. Shedlock, PhD, on Shifting from Autologous to Allogeneic Therapies


The chief scientific officer of cell therapy at Poseida Therapeutics discussed the company’s CAR-T and TCR technologies.

“We have developed an allogeneic CAR-T platform that we're expanding into TCRs. The nice thing about our platform is that because we're using the PiggyBac transposon technology, we’re able to have a larger CAR capacity. That easily enables the coexpression of a TCR along with a safety switch and a selection gene, with a CAR included as well.I think that's something that we can really leverage in our approach.”

Devon J. Shedlock, PhD, chief scientific officer, cell therapy, at Poseida Therapeutics, gave a presentation entitled “A Fully Allogeneic Tscm-based TCR-T Platform for Cncology & Beyond” on Poseida’s emerging technologies at the 7th Annual CAR-TCR Summit, held September 19-22, 2022, in Boston, Massachusetts.

Poseida Therapeutics is developing a pipeline of autologous and allogeneic chimeric antigen receptor (CAR) T-cell therapies for the treatment of both solid and liquid tumors, as well as rare diseases and hematological conditions. In his presentation, Shedlock discussed the company’s shift towards T-cell receptor (TCR) therapies and allogeneic therapies and the reasons behind this.

Shedlock discussed the Poseida’s TCR platform and its advantages in an interview with CGTLive. He touched on 2 of the company’s lead allogeneic programs right now, P-MUC1C-ALLO1 for solid tumors and P-BCMA-ALLO1 for multiple myeloma. He also shared his thoughts on why allogeneic CAR Ts are the future of the cell therapy space.

Shedlock D. A fully allogeneic Tscm-based TCR-T platform for oncology & beyond. Presented at: 7th Annual CAR-TCR Summit. September 19-22, 2022; Boston, Massachusetts.
Related Videos
Dilsher Dhoot, MD, on a Promising Start With Diabetic Retinopathy Gene Therapy RGX-314
J. Andrew Livingston, MD, on Forging Forward With Novel Sarcoma Trials
Shankar Musunuri, PhD, on Gene Modifier Therapy vs Gene Replacement Therapy for IRDs
Pat Furlong, BSN, RN, on the State of Gene Therapy in Muscular Dystrophy
Michael Kelly, PhD, on Continuing Progress With Gene Therapy in Muscular Dystrophy
Thomas McCauley, PhD, on Potential Advantages of Epigenetic Therapy Over Small Molecule, Gene Therapy
© 2023 MJH Life Sciences

All rights reserved.